ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1417	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version	Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary.	randomized placebo-controlled trial 0.595383 gastric adenomatous polyps 0.679902 experimental animal models 0.575229 infected family members 0.578256 antioxidant dietary supplements 0.574787 H. pylori 0.663672 annual incidence rates 0.588818 secondary prevention measures 0.572741 age-adjusted incidence rate 0.59463 statistically significant reduction 0.578799 combined antioxidant groups 0.572868 H. pylori infection 0.650947 high H. pylori 0.585004 family members 0.581961 gastric cancer mortality 0.686327 endoscopic resection techniques 0.578064 placebo group 0.585452 chemoprevention trial 0.590009 H. pylori-infected family 0.583244 Li Fraumeni syndrome 0.58425 intestinal metaplasia 0.628781 advanced premalignant lesions 0.570945 protective effects 0.575049 low selenium content 0.586292	statistically significant effect 0.623477 Beta Carotene trial 0.587524 United States 0.702911 gastric cancer incidence. 0.664051 precancerous gastric lesions. 0.647932 5-year survival rate 0.635247 gastric cancer cases 0.674324 gastric cancers 0.625749 gastrointestinal cancers 0.575893 H. pylori-infected people 0.581367 overall 5-year survival 0.57409 beta carotene 0.671292 small randomized trial 0.598139 gastric cancer 0.97116 gastric adenocarcinoma. 0.625249 eradication therapy 0.572355 Chinese medical journal 0.572216 vitamin supplementation 0.570623 statistically significant regression 0.573687 chronic atrophic gastritis 0.586209 gastric cancer. 0.610162 close family members. 0.576811 family history 0.58364 steady incidence rates 0.587586	CLICK HERE
1666	National Cancer Institute	Html	en	Testicular Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for testicular cancer.	testicular self-exams 0.545422 ongoing clinical trials 0.499986 PDQ cancer information 0.758311 testicular cancer 0.955987 testicular germ cell 0.59857 testicular carcinoma 0.546926 NCI Web site 0.507088 testicular cancers 0.553122 clinical trials 0.669739 early detection 0.495849 germ cells 0.505641 cancer information summary 0.64569 clinical trial 0.511819 breast cancer prevention 0.524202 spermatic cord 0.49407 PDQ summaries 0.534816 cancer patients 0.49191 latest published information 0.509374 NCI’s PDQ 0.538459 cancer symptoms 0.51215 NCI PDQ cancer 0.620022 tests 0.527688 testicular cancer screening 0.701295 routine screening test 0.519043	PDQ Screening 0.553678 testicles 0.486139 screening tests 0.48752 Cancer Information Service 0.545478 common cancer 0.501504 male sex glands 0.496865 Prevention Editorial Board 0.56412 treatment clinical trials 0.501604 National Cancer Institute 0.653794 PDQ documents 0.525451 cancer doctors 0.485997 long coiled tube 0.493438 new treatment 0.506259 health professional version 0.485461 Cancer screening trials 0.571582 PDQ database 0.532773 Cancer Care page 0.527585 Testicular Cancer Treatment 0.685082 risk factor 0.499445 PDQ summary 0.654344 routine physical exam 0.576949 cancer information summaries 0.554625 health professional versions 0.489301 comprehensive cancer information 0.555761	CLICK HERE
1716	National Cancer Institute	Html	en	Human Papillomavirus (HPV) Vaccines	A fact sheet about human papillomavirus (HPV) vaccines for the prevention of infection with certain types of HPV, which is the major cause of cervical cancer.	transmitted HPV types 0.372301 HPV prophylactic vaccines 0.352103 anal HPV 0.291899 HPV transmission 0.315597 available HPV vaccine 0.365066 HPV types 0.787213 Disease Control 0.208664 HPV vaccination coverage 0.329587 HPV vaccination program 0.333099 bivalent HPV vaccination 0.335395 hpv vaccination 0.566558 cervical cancer 0.335142 high-risk HPV infections 0.38085 HPV surface components 0.326712 genital HPV infection 0.36709 available HPV vaccines 0.389305 persistent HPV 0.314117 high-risk hpv types 0.523029 HPV vaccines 0.696012 human papillomavirus 0.38319 HPV vaccination series 0.361602 HPV infections 0.517426 genital HPV infections 0.379278 contact.  HPV infections 0.352636 human papillomavirus vaccine 0.256852	hpv infection 0.466234 current HPV vaccines 0.379891 women 0.226009 United States 0.375279 Updated HPV Vaccination 0.330423 current HPV infections 0.328908 therapeutic HPV vaccines 0.356162 human papillomavirus vaccines 0.212379 HPV Vaccination Recommendations 0.367966 Yes. Because HPV 0.297056 dozen high-risk HPV 0.362742 HPV 0.924148 routine HPV vaccination 0.357555 genital warts 0.26905 quadrivalent HPV vaccine 0.329163 additional HPV types 0.3896 quadrivalent human papillomavirus 0.21339 HPV vaccine product 0.372857 additional high-risk HPV 0.343778 currently approved HPV 0.315107 high-risk HPV type 0.392493 Gardasil 0.309437 vaccine-targeted HPV types 0.33361 et al 0.409031	CLICK HERE
1858	National Cancer Institute	Html	es	Tratamiento del cáncer de glándulas salivales (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de glándulas salivales.	salivary gland carcinoma 0.756611 salivary neoplasms 0.424559 estroma linfoide 0.413137 prognostic factors 0.41902 gland tumours 0.43032 Spiro RH 0.465562 Sin embargo 0.429856 advanced salivary 0.421758 Malignant parotid tumors 0.41189 minor salivary 0.423431 tumores benignos 0.597781 Salivary Gland Disease 0.423228 tumores malignos mixtos 0.484605 botulinum toxin 0.428989 Radiat Oncol Biol 0.471433 glándulas salivales benignos 0.570833 neck neoplasia following 0.437258 fuerte predilección 0.414088 Parotid gland tumours 0.420714 salivary gland 0.859636 Head Neck Surg 0.476609 mucoepidermoid carcinoma 0.597885 gland malignant neoplasms 0.445484 tumores benignos mixtos 0.438326 único síntoma 0.425265	parotid gland 0.431427 lesiones carcinoma 0.466113 relativa frecuencia 0.450675 sección carcinoma 0.486375 carcinoma ex-tumor 0.470245 unresectable carcinomas 0.426636 Oral Oncol 0.420027 major salivary glands 0.414421 Otolaryngol Head Neck 0.413034 término carcinoma 0.475993 carcinoma epidermoide 0.472012 edad promedio 0.670934 Salivary Gland Tumours 0.424182 carcinoma with 0.481329 adenocarcinoma sai 0.463524 carcinoma salival basaloide 0.481935 carcinomas quísticos adenoides 0.459095 Botulinum toxin treatment 0.413697 with parotid carcinoma 0.483397 Oncol Biol Phys 0.47266 linfadenoma sebáceo 0.417003 elemento carcinoma 0.475416 carcinoma mucoepidermoide 0.988653 neoplasias benignas 0.45166	CLICK HERE
1861	National Cancer Institute	Html	es	Tratamiento del cáncer de orofaringe (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de orofaringe.	Tabor MP 0.407217 enfermedad oral benigna 0.333898 antecedentes ganglionares n2b–n3 0.348129 nivel v 0.341116 M0 TX 0.345233 CA Cancer 0.341917 squamous epithelium 0.334337 cirugía transoral versus 0.32767 Cancer Res 0.419675 clinical implications 0.349857 DeVita VT Jr 0.346296 Human papillomavirus infection 0.357131 VPH tipo 0.33416 Natl Cancer Inst 0.562443 enfermedad t4 0.338752 nivel ii 0.349773 neck cancers 0.968755 human papillomavirus 0.694615 orofaringe estadio 0.33767 Head Neck Surg 0.342719 second primary tumors 0.391083 Mendenhall WM 0.327697 Head Neck 0.399598 estadio iv 0.354503 M0 T2 0.385934	M0 T1 0.384478 M0 T3 0.425033 radioterapia posoperatoria 0.399508 oral stratified squamous 0.327772 definiciones tnm 0.328717 Cancer Staging Manual 0.397433 múltiples ganglios 0.776893 cirugía versus 0.380943 Epidemiol Biomarkers Prev 0.350461 Alto VPH 0.331071 neck retinoid chemoprevention 0.329578 oropharyngeal cancers versus 0.33045 ganglios retrofaríngeos 0.460243 Oral Pathol Med 0.327912 MD Anderson Cancer 0.350182 index tumor site 0.345356 field cancerization 0.375139 ganglios linfáticos retrofaríngeos 0.70114 M0 Tis 0.349862 Braakhuis BJ 0.34369 oropharyngeal cancer 0.750404 M0 T4a 0.419704 neck tumors frequently 0.331875 AJCC Cancer Staging 0.401717	CLICK HERE
1989	National Cancer Institute	Html	es	Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer.	etapa final 0.974283 posibles efectos tardíos 0.445113 células madre 0.448459 adultos jóvenes 0.631616 personas jóvenes 0.478657 posibles tratamientos 0.424654 siguientes aspectos 0.421705 cáncer causa estrés 0.501532 apoyo social escaso 0.437899 siguientes tipos 0.415041 largo plazo 0.418906 efectos tardíos 0.530812 familia reaccionarán 0.418853 National Cancer Institute 0.415958 siguientes riesgos 0.411551	siguientes maneras 0.446878 Instituto Nacional 0.427962 síntomasEl trastorno 0.423462 Cuidado paliativo 0.412419 distintos miembros 0.413316 tratamiento ayuda 0.457106 suicidioUn número 0.419685 siguientes efectos 0.419968 posibles efectos 0.465562 Physician Data Query 0.458553 sistema nervioso central 0.433857 mayores probabilidades 0.421125 Estados Unidos 0.416849 mejores tratamientos 0.417691	CLICK HERE
3460	National Cancer Institute	Html	es	Coenzima Q10 (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre el uso de la coenzima Q10 como tratamiento para las personas con cáncer.	Natl Acad Sci 0.506232 animal models 0.503048 Lockwood K 0.522246 Friend leukemia virus 0.50335 Mol Aspects Med 0.525442 Prog Drug Res 0.505422 Exp Clin Res 0.507107 Ernster L 0.506157 Clin Investig 0.504327 vitamina q10 0.508703 vitamin q10 0.549224 Health Syst Pharm 0.503499 Chem Pathol Pharmacol 0.515808 Bliznakov EG 0.512562 Hanioka T 0.504235 coenzyme q10 0.845306 with vitamin q10 0.522905 reticuloendothelial system upon 0.50329 Res Commun Chem 0.525595 coenzima q10 0.990386 Nylander M 0.503126 system upon stimulation 0.503357 coenzima q.10 0.50372 Coenzyme Q10 administration 0.515239 patients with 0.52239	Clinical Aspects 0.506167 Folkers K 0.720923 patients treated with 0.503528 Osterborg A 0.503093 coenzima q10 resumen 0.509859 Commun Chem Pathol 0.52121 Moesgaard S 0.509545 Biophys Res Commun 0.66246 Chemother Rep 0.503476 Nordenbrand K 0.502764 Proc Natl Acad 0.506461 Apparent partial remission 0.503092 Biochem Biophys Res 0.653978 with nutritional antioxidants 0.504649 coenzima q10 ayuda 0.51293 Drugs Exp Clin 0.50459 conzima q10 0.506965 Overvad K 0.504381 Clin Nutr 0.503026 serious deficiency 0.503488 coenzyme q10 concentrations 0.523415 radicales libres 0.504036 essential fatty acids 0.503269 Yamashita S 0.503124	CLICK HERE
4300	National Cancer Institute	Html	en	Cancer Moonshot℠ Blue Ribbon Panel	The Blue Ribbon Panel Report outlines 10 recommendations to accelerate progress against cancer. The panel was established to ensure that the Cancer Moonshot's approaches are grounded in the best science.	BRP 0.544911 National Cancer Advisory 0.917882 pediatric cancer 0.537601 relevant scientific sectors 0.512578 Reduce cancer risk 0.54942 dynamic 3D maps 0.479491 early detection 0.494934 therapeutic targets 0.493364 presidentially appointed National 0.528792 new preclinical models 0.493659 national cancer data 0.584851 previously effective treatments 0.485016 early detection strategies 0.482919 new therapeutic targets 0.480719 cancer resistance 0.471789 E. Intensify research 0.49241 translational science network 0.495254 cancer technologies 0.513048 public idea submission 0.473834 broader cancer community 0.579774 transformative research recommendations 0.554836 cancer immunotherapy network 0.593107 Ribbon Panel report 0.661804 tumor evolution 0.579883	cancer health disparities 0.557334 final recommendations 0.465114 Cancer Immunology 0.464811 human tumor evolution 0.504864 specific recommendations 0.466439 cancer prevention 0.548373 C. Develop ways 0.499508 tumor profile data 0.530939 cancer cells 0.472187 group members 0.429792 Minimize cancer treatment 0.561924 direct patient involvement 0.494413 joint recommendations 0.465939 3D cancer atlas 0.546232 multiple groups 0.44011 Cancer Moonshot Task 0.60025 Blue Ribbon Panel 0.890429 groups 0.493987 BRP members 0.537843 major topic areas 0.508582 Cancer Advisory Board 0.925259 efficient data analysis 0.49446 Develop new cancer 0.562862 future patient outcomes 0.484191	CLICK HERE
16842	National Cancer Institute	Html	en	Johns Hopkins University — Predoctoral and Postdoctoral Training Program in Nanotechnology for Cancer Research	The focus of the Johns Hopkins University Cancer Nanotechnology Training Center is presented here.	predoctoral fellows 0.736483 cancer nanobiotechnology 0.632531 optimal treatment 0.545276 Johns Hopkins University 0.729715 journal club 0.539106 novel cancer diagnostics 0.713403 program fosters 0.562779 steady state number 0.670018 epigenetic markers 0.560601 tumor boards 0.538166 NTCR program 0.576419 new frontier 0.564875 individual patient 0.643505 engineering/physics discipline 0.563571 physical sciences-oncology center 0.676488 lab course 0.540911 new modalities 0.563 cellular / cancer 0.59221 Johns Hopkins Institute 0.669855 dedicated annual symposium 0.651728 experimental facilities 0.538368 Vivo Cellular 0.548936 Molecular Imaging Center 0.688968 black-box input-output techniques 0.710638	scientific exploration 0.554225 clinical resources 0.5443 human diseases 0.555299 cancer cell functions 0.720912 clinical conferences 0.540551 high-throughput diagnostic tools 0.682779 non-viral delivery systems 0.686087 unique educational resources 0.657197 postdoctoral fellows 0.715577 Principal Investigator 0.564913 therapeutic tools 0.551025 Pancreatic Cancer Center 0.731915 Ludwick Center 0.581555 NTCR trainees 0.59515 cancer nanotechnology excellence 0.742492 outstanding trainees 0.578764 disease phenotype 0.55677 Comprehensive Cancer Center 0.727928 Cancer Genetics 0.585039 NTCR fellows 0.742981 engineer novel drug/antibody/siRNA 0.668859 human cancers 0.551276 core courses 0.541397 Training Focus 0.565904	CLICK HERE
16852	National Cancer Institute	Html	en	University of California, San Diego — Cancer Research in Nanotechnology (CRIN)	Provides trainees with a balanced combination comprehensive cancer biology, engineering, and entrepreneurship didactic training, including cancer researcher, clinical/translational cancer faculty, and practical skills in small business environments.	synergy 0.439136 dearth 0.464725 promise 0.439416 issues 0.469099 oral presentations 0.597869 investigators 0.43726 San Diego 0.64989 spite 0.453494 academia 0.440105 research advances 0.635659 academic mentors 0.611308 Ph.D. 0.437454 nanotechnology 0.493685 medical device 0.611406 cancer therapies 0.658537 California 0.440505 engineering/materials science 0.617993 University 0.440535 success 0.436075 comprehensive set 0.611033 training program 0.629484 clinical/translational cancer faculty 0.809173 Current PhD 0.611308 comprehensive cancer biology 0.812096 trainees 0.625803	cross training 0.614905 postdoctoral training 0.632853 CRIN 0.480296 cancer research 0.980901 science cancer researcher 0.808302 present research proposals 0.781791 laboratory experience 0.604598 practical skills 0.600189 National Cancer Institute 0.811595 Principal Investigator 0.635275 young scientists 0.755823 small firm 0.611549 cancer. 0.433521 Dong-Er Zhang 0.641012 entrepreneurship didactic training 0.808298 academia. 0.434053 life.  Engineering approaches 0.803444 Andrew Kummel 0.630977 application 0.436257 discoveries 0.437754 device companies 0.613133 cancer biology 0.906785 small business entrepreneurs 0.772007 academic career path 0.764024	CLICK HERE